Literature DB >> 7720182

Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig.

G Laurell1, A Andersson, B Engström, H Ehrsson.   

Abstract

The concentration of free cisplatin was followed in plasma, scala tympani perilymph and cerebrospinal fluid (CSF) after an intravenous injection (12.5 mg/kg) in guinea pigs. Liquid chromatography with postcolumn derivatization was used for quantitative determination of the drug. The distribution of cisplatin to CSF was fast; at 10 min after drug administration the concentration was 7 micrograms/ml and the CSF:plasma ratio was 0.37. Cisplatin seems to distribute more slowly to the perilymphatic compartment. The highest concentration measured was 4 micrograms/ml at 20 min after the injection, and the perilymph:plasma ratio was 0.40 at that time. The concentration-time curves generated for cisplatin in perilymph and CSF were similar. No accumulation in the perilymphatic compartment or CSF was observed.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7720182     DOI： 10.1007/BF00685738

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  23 in total

1.  Perilymph composition in scala tympani of the cochlea: influence of cerebrospinal fluid.

Authors:  A Hara; A N Salt; R Thalmann
Journal:  Hear Res       Date:  1989-11       Impact factor: 3.208

2.  Volume flow rate of perilymph in the guinea-pig cochlea.

Authors:  K Ohyama; A N Salt; R Thalmann
Journal:  Hear Res       Date:  1988-09-15       Impact factor: 3.208

3.  Optimal treatment for advanced seminoma?

Authors:  R J Motzer
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

4.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Authors:  D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

5.  Cerebrospinal fluid-platinum kinetics of cisplatin in man.

Authors:  J P Armand; J P Macquet; A F LeRoy
Journal:  Cancer Treat Rep       Date:  1983-11

6.  High-dose cisplatin treatment: hearing loss and plasma concentrations.

Authors:  G Laurell; U Jungnelius
Journal:  Laryngoscope       Date:  1990-07       Impact factor: 3.325

7.  Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.

Authors:  P Tran Ba Huy; P Bernard; J Schacht
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.

Authors:  J Kopelman; A S Budnick; R B Sessions; M B Kramer; G Y Wong
Journal:  Laryngoscope       Date:  1988-08       Impact factor: 3.325

9.  Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate.

Authors:  A Andersson; H Ehrsson
Journal:  J Chromatogr       Date:  1994-02-11

10.  High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

Authors:  D M Hayes; E Cvitkovic; R B Golbey; E Scheiner; L Helson; I H Krakoff
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860
View more
  8 in total

1.  Comparison of cochlear cell death caused by cisplatin, alone and in combination with furosemide.

Authors:  Li Xia; Zhengnong Chen; Kaiming Su; Shankai Yin; Jian Wang
Journal:  Toxicol Pathol       Date:  2013-04-02       Impact factor: 1.902

2.  Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer.

Authors:  Katsuhiro Masago; Yoshitsugu Horio; Shiro Fujita; Yasushi Yatabe
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Functional and structural changes in the chinchilla cochlea and vestibular system following round window application of carboplatin.

Authors:  Yide Zhou; Dalian Ding; Kari Suzanne Kraus; Dongzhen Yu; Richard J Salvi
Journal:  Audiol Med       Date:  2009-12-01

4.  Cool OtOprotective Ear Lumen (COOL) Therapy for Cisplatin-induced Hearing Loss.

Authors:  James K Stanford; Drew S Morgan; Nicholas A Bosworth; Georgio Proctor; Tianwen Chen; Trace T Palmer; Punam Thapa; Bradley J Walters; Douglas E Vetter; Robert D Black; Lesco L Rogers; Christopher Spankovich
Journal:  Otol Neurotol       Date:  2021-03-01       Impact factor: 2.311

5.  Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.

Authors:  Guiscardo Lorito; Stavros Hatzopoulos; Göran Laurell; Kathleen C M Campbell; Joseph Petruccelli; Pietro Giordano; Krzysztof Kochanek; Lech Sliwa; Alessandro Martini; Henryk Skarzynski
Journal:  Med Sci Monit       Date:  2011-08

6.  Hydrogen Inhalation Protects against Ototoxicity Induced by Intravenous Cisplatin in the Guinea Pig.

Authors:  Anette E Fransson; Marta Kisiel; Kristian Pirttilä; Curt Pettersson; Pernilla Videhult Pierre; Göran F E Laurell
Journal:  Front Cell Neurosci       Date:  2017-09-13       Impact factor: 5.505

7.  Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application.

Authors:  Ronald J Schroeder; Jason Audlin; Juntao Luo; Brian D Nicholas
Journal:  J Otol       Date:  2018-02-09

8.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.